Table 3 Clinical data and prognosis analysis of HER2-positive patients in the GC and RC48 groups
|  | Total | TURBT + GC | TURBT + RC48-ADC | P |
|---|---|---|---|---|
N (%) | 125(100%) | 83(66.4%) | 42(33.6%) | Â |
Gender | Â | Â | Â | 0.622 |
 Male | 98(78.4%) | 64(51.2%) | 34(27.2%) |  |
 Female | 27(21.6%) | 19(15.2%) | 8(6.4%) |  |
Tumor size (cm) | Â | Â | Â | 0.856 |
 ≤ 3 | 52(41.6%) | 35(28.0%) | 17(13.6%) |  |
 > 3 | 73(58.4%) | 48(38.4%) | 25(20.0%) |  |
Single or multiple | Â | Â | Â | 0.284 |
 Single | 56(44.8%) | 40(32.0%) | 16(12.8%) |  |
 Multiple | 69(55.2%) | 43(34.4%) | 26(20.8%) |  |
Clinical stages | Â | Â | Â | 0.068 |
 T2 | 48(38.4%) | 29(23.2%) | 19(15.2%) |  |
 T3 | 77(61.6%) | 54(43.2%) | 23(18.4%) |  |
Pathological grade | Â | Â | Â | 0.434 |
 Low grade | 29(23.2%) | 21(16.8%) | 8(6.4%) |  |
 High grade | 96(76.8%) | 62(49.6%) | 34(27.2%) |  |
Pelvic lymph nodes | Â | Â | Â | 0.537 |
 Yes | 23(18.4%) | 15(12.0%) | 8(6.4%) |  |
 No | 102(81.6%) | 68(54.4%) | 34(27.2%) |  |
ECOG PS | Â | Â | Â | 0.615 |
 0 | 86(68.8%) | 60(48.0%) | 26(20.8%) |  |
 1–2 | 36(28.8%) | 22(17.6%) | 14(11.2%) |  |
 3–4 | 3(2.4%) | 1(0.8%) | 2(1.6%) |  |
Recurrence | Â | Â | Â | 0.001 |
 Yes | 71(56.8%) | 56(44.8%) | 15(12.0%) |  |
 No | 54(43.2%) | 27(21.6%) | 27(21.6%) |  |
Median recurrence-free survival time (95% CI) | - | 19.0(10.3–27.7) | - |  < 0.001 |
Death | Â | Â | Â | 0.004 |
 Yes | 24(19.2%) | 22(17.6%) | 2(1.6%) |  |
 No | 101(80.8%) | 61(48.8%) | 40(32.0%) |  |
Median overall survival time (95% CI) | - | 56.0(45.7–66.3) | - |  < 0.001 |